• Earlier this month, Clorox completed three US$400.00 million–US$550.00 million fixed-rate bond offerings maturing between 2031 and 2036, while its leadership prepared to address investors at a global consumer conference.
• The mix of new long-term debt, cautious commentary around margins and market share recovery, and ongoing integration efforts has sharpened investor focus on how Clorox balances growth investments with balance sheet resilience.
• With management acknowledging slower-than-hoped market share recovery and issuing more cautious guidance, we’ll now examine how this updates Clorox’s investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Clorox Investment Narrative Recap

To own Clorox today, you need to believe that its brands, cost initiatives and digital investments can overcome slow category growth, pricing pressure and elevated debt. The recent US$1.5 billion in fixed rate bond issuance, alongside softer guidance and slower share recovery, keeps the near term earnings trajectory and balance sheet risk in sharp focus, but does not fundamentally alter the core debate around demand resilience and margin durability.

The most relevant update here is the lowered fiscal 2026 EPS guidance to US$4.78 to US$4.98, which came just before the bond deals. That guidance already bakes in ERP noise and GOJO costs, and sets a lower profitability bar against which investors will judge how effectively the new long term debt supports integration, productivity and innovation efforts without stretching cash flows.

Yet beneath the appeal of stable brands, investors should still be aware of how rising debt and slower market share recovery could...

Clorox's narrative projects $7.9 billion revenue and $911.5 million earnings by 2029. This requires 5.2% yearly revenue growth and a $156.5 million earnings increase from $755.0 million.

Uncover how Clorox's forecasts yield a $115.47 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue around US$7.9 billion and earnings near US$896.7 million by 2029, so if you worry that slower innovation and rising environmental costs could bite harder than expected, their more pessimistic reading of the latest bond issuance and guidance cuts may resonate with you more than the consensus view.

Explore 7 other fair value estimates on Clorox - why the stock might be worth just $91.12!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Clorox research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.